High density lipoprotein cholesterol: An evolving target of therapy in the management of cardiovascular disease

Navin K. Kapur, Dominique Ashen, Roger S Blumenthal

Research output: Contribution to journalArticle

Abstract

Since the pioneering work of John Gofman in the 1950s, our understanding of high density lipoprotein cholesterol (HDL-C) and its relationship to coronary heart disease (CHD) has grown substantially. Numerous clinical trials since the Framingham Study in 1977 have demonstrated an inverse relationship between HDL-C and one's risk of developing CHD. Over the past two decades, preclinical research has gained further insight into the nature of HDL-C metabolism, specifically regarding the ability of HDL-C to promote reverse cholesterol transport (RCT). Recent attempts to harness HDL's ability to enhance RCT have revealed the complexity of HDL-C metabolism. This review provides a detailed update on HDL-C as an evolving therapeutic target in the management of cardiovascular disease.

Original languageEnglish (US)
Pages (from-to)39-57
Number of pages19
JournalVascular Health and Risk Management
Volume4
Issue number1
DOIs
StatePublished - 2008

Fingerprint

HDL Cholesterol
Cardiovascular Diseases
Coronary Disease
Therapeutics
Cholesterol
Clinical Trials
Research

Keywords

  • Atherosclerosis
  • Coronary
  • High density lipoprotein cholesterol (HDL-C)
  • Reverse cholesterol transport

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)
  • Public Health, Environmental and Occupational Health
  • Hematology
  • Endocrinology, Diabetes and Metabolism

Cite this

High density lipoprotein cholesterol : An evolving target of therapy in the management of cardiovascular disease. / Kapur, Navin K.; Ashen, Dominique; Blumenthal, Roger S.

In: Vascular Health and Risk Management, Vol. 4, No. 1, 2008, p. 39-57.

Research output: Contribution to journalArticle

@article{e5c50203623840599a443d992137205f,
title = "High density lipoprotein cholesterol: An evolving target of therapy in the management of cardiovascular disease",
abstract = "Since the pioneering work of John Gofman in the 1950s, our understanding of high density lipoprotein cholesterol (HDL-C) and its relationship to coronary heart disease (CHD) has grown substantially. Numerous clinical trials since the Framingham Study in 1977 have demonstrated an inverse relationship between HDL-C and one's risk of developing CHD. Over the past two decades, preclinical research has gained further insight into the nature of HDL-C metabolism, specifically regarding the ability of HDL-C to promote reverse cholesterol transport (RCT). Recent attempts to harness HDL's ability to enhance RCT have revealed the complexity of HDL-C metabolism. This review provides a detailed update on HDL-C as an evolving therapeutic target in the management of cardiovascular disease.",
keywords = "Atherosclerosis, Coronary, High density lipoprotein cholesterol (HDL-C), Reverse cholesterol transport",
author = "Kapur, {Navin K.} and Dominique Ashen and Blumenthal, {Roger S}",
year = "2008",
doi = "10.2147/vhrm.2008.04.01.39",
language = "English (US)",
volume = "4",
pages = "39--57",
journal = "Vascular Health and Risk Management",
issn = "1176-6344",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - High density lipoprotein cholesterol

T2 - An evolving target of therapy in the management of cardiovascular disease

AU - Kapur, Navin K.

AU - Ashen, Dominique

AU - Blumenthal, Roger S

PY - 2008

Y1 - 2008

N2 - Since the pioneering work of John Gofman in the 1950s, our understanding of high density lipoprotein cholesterol (HDL-C) and its relationship to coronary heart disease (CHD) has grown substantially. Numerous clinical trials since the Framingham Study in 1977 have demonstrated an inverse relationship between HDL-C and one's risk of developing CHD. Over the past two decades, preclinical research has gained further insight into the nature of HDL-C metabolism, specifically regarding the ability of HDL-C to promote reverse cholesterol transport (RCT). Recent attempts to harness HDL's ability to enhance RCT have revealed the complexity of HDL-C metabolism. This review provides a detailed update on HDL-C as an evolving therapeutic target in the management of cardiovascular disease.

AB - Since the pioneering work of John Gofman in the 1950s, our understanding of high density lipoprotein cholesterol (HDL-C) and its relationship to coronary heart disease (CHD) has grown substantially. Numerous clinical trials since the Framingham Study in 1977 have demonstrated an inverse relationship between HDL-C and one's risk of developing CHD. Over the past two decades, preclinical research has gained further insight into the nature of HDL-C metabolism, specifically regarding the ability of HDL-C to promote reverse cholesterol transport (RCT). Recent attempts to harness HDL's ability to enhance RCT have revealed the complexity of HDL-C metabolism. This review provides a detailed update on HDL-C as an evolving therapeutic target in the management of cardiovascular disease.

KW - Atherosclerosis

KW - Coronary

KW - High density lipoprotein cholesterol (HDL-C)

KW - Reverse cholesterol transport

UR - http://www.scopus.com/inward/record.url?scp=41549091835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41549091835&partnerID=8YFLogxK

U2 - 10.2147/vhrm.2008.04.01.39

DO - 10.2147/vhrm.2008.04.01.39

M3 - Article

C2 - 18629371

AN - SCOPUS:41549091835

VL - 4

SP - 39

EP - 57

JO - Vascular Health and Risk Management

JF - Vascular Health and Risk Management

SN - 1176-6344

IS - 1

ER -